To evaluate the value of MRI for surveillance of primary hemi-HIFU therapy for localized PCa in a single-center.
Patients with localized prostate cancer were treated with hemi-HIFU from October 2009 to March 2014. All patients performed MRI before focal therapy, the reader was blinded to the treatment. Oncological failure was defined as positive biopsy or biochemical recurrence (Phoenix).
Twenty-five patients were treated with hemi-HIFU in one center. The median nadir PSA was 1.45±1.4ng/mL. Prostate volume decreased from 45 cc to 25 cc on MRI findings. At 20 months, none of the patients had histological recurrence. Biochemical-free survival rate was 88%. MRI evaluation had a negative predictive value of 100% on the treated area and 81% on the untreated area. PSAd≥0.1ng/mL(2) was a predictive factor for cancer on untreated area (P=0.042).
MRI control at 6 months is a potentially effective evaluation of treated area after hemi-HIFU and may replace randomized biopsies if PSAd<0.1ng/mL(2) during follow-up.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2016 Aug 24 [Epub ahead of print]
L Hoquetis, B Malavaud, X Game, J B Beauval, D Portalez, M Soulie, P Rischmann
Urology department, Rangueil university hospital, 1, avenue du Pr-Jean-Poulhes, 31059 Toulouse cedex, France. Electronic address: ., Urology department, Rangueil university hospital, 1, avenue du Pr-Jean-Poulhes, 31059 Toulouse cedex, France.